Societal CDMO Reports Inducement Grants for New Staff
06. April 2022 16:05 ET
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation
21. März 2022 07:00 ET
|
Recro Pharma, Inc.
With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers’ Goal of Delivering Impactful Medicines to SocietyNew...
Recro Reports Fourth Quarter and Year End 2021 Financial Results
01. März 2022 16:05 ET
|
Recro Pharma, Inc.
Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew...
Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility
23. Februar 2022 07:00 ET
|
Recro Pharma, Inc.
SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to...
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
22. Februar 2022 16:05 ET
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention
26. Januar 2022 07:00 ET
|
Recro Pharma, Inc.
SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro Reports Inducement Grants For New Staff
06. Januar 2022 16:05 ET
|
Recro Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
03. Januar 2022 07:00 ET
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro to Present at Stephens Annual Investment Conference
02. Dezember 2021 07:00 ET
|
Recro Pharma, Inc.
SAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving...
Recro Reports Third Quarter 2021 Financial Results
09. November 2021 16:05 ET
|
Recro Pharma, Inc.
Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of...